TABLE 3

Logan- and SRTM-Derived BP_ND Values for ¹⁸F-AMC20

	Logan BP_ND		SRTM BP_ND
ROI	Control	Raclopride	Control	Raclopride
Striatum	0.49 ± 0.09	0.36 ± 0.07 (−26%)^*	0.49 ± 0.08	0.35 ± 0.07 (–29%)^†
Hippocampus	0.35 ± 0.06	0.35 ± 0.08 (0%)	0.37 ± 0.05	0.34 ± 0.09 (–6%)
Thalamus	0.39 ± 0.05	0.36 ± 0.09 (−10%)	0.39 ± 0.05	0.32 ± 0.07 (–19%)
Hypothalamus	0.20 ± 0.08	0.13 ± 0.05 (−35%)	0.14 ± 0.09	0.12 ± 0.05 (–14%)
Cortex	0.09 ± 0.03	0.11 ± 0.07 (22%)	0.08 ± 0.01	0.10 ± 0.06 (+18%)
Brain stem	0.29 ± 0.08	0.16 ± 0.04 (−43%)^†	0.29 ± 0.08	0.14 ± 0.03 (–53%)^†
Olfactory bulbs	0.06 ± 0.05	0.07 ± 0.10 (25%)	0.07 ± 0.05	0.07 ± 0.12 (+2%)
Pituitary	0.09 ± 0.11	0.06 ± 0.09 (−36%)	0.15 ± 0.13	0.07 ± 0.10 (–55%)

↵* P < 0.07, 2-sided Welch test.
↵† P < 0.05, 2-sided Welch test.
Data are mean ± SD (n = 4/treatment group). Change in BP_ND value after raclopride challenge relative to control group is shown in parentheses. 1TCM- and 2TCM-derived BP_ND values are presented in Supplemental Table 4.